Physician profile
Danielle Elyse Haswell
NPI 1457998114
$1,075.53
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $941 · 2022: $56.40 · 2023: $59.82 · 2024: $18.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $78.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $78.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $271.65 | 2021 | |
| Myovant Sciences INC. | $195.61 | 2021 | |
| Dendreon Pharmaceuticals LLC | $121.43 | 2021-2022 | |
| Abbvie INC. | $117.40 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $69.96 | 2021 | |
| Blue Earth Diagnostics | $59.14 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.69 | 2021 | |
| 180 Medical, INC. | $29.93 | 2021 | |
| Coloplast Corp | $27.77 | 2023 | Speedicath, Porges Coloplast |
| Merck Sharp & Dohme LLC | $22.43 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $20.34 | 2021 | |
| Boston Scientific Corporation | $18.99 | 2021 | |
| Janssen Pharmaceuticals, INC | $17.13 | 2023 | Xarelto |
| Urovant Sciences INC | $16.55 | 2021 | |
| Amgen INC. | $16.36 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $14.08 | 2021 | |
| Endo Pharmaceuticals INC. | $11.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Haswell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.